首页> 美国卫生研究院文献>Pharmaceutics >Preparation Characterization and Pharmacokinetic Evaluation of Imperatorin Lipid Microspheres and Their Effect on the Proliferation of MDA-MB-231 Cells
【2h】

Preparation Characterization and Pharmacokinetic Evaluation of Imperatorin Lipid Microspheres and Their Effect on the Proliferation of MDA-MB-231 Cells

机译:欧前胡素脂质微球的制备表征药代动力学评价及其对MDA-MB-231细胞增殖的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Imperatorin is a chemical compound belonging to the linear furanocoumarins. Imperatorin is attracting considerable attention because of its antitumor, antibacterial, anti-inflammatory, and anticoagulant activities, inhibition of myocardial hypertrophy, and other pharmacological efficacies. However, imperatorin has limited water solubility and has better lipid solubility; thus, we decided to design and synthesize imperatorin lipid microspheres to optimize the preparation conditions. The aim was to develop and formulate imperatorin lipid microspheres through nanoemulsion technology and apply the response surface–central composite design to optimize the imperatorin lipid microsphere formulation. The influence of the amounts of egg lecithin, poloxamer 188, and soybean oil for injection on the total percentage of the oil phase was investigated. The integrated effect of dependent variables, including particle size, polydispersity index, zeta potentials, drug loading, and encapsulation efficiency, was investigated. Data of overall desirabilities were fitted to a second-order polynomial equation, through which three-dimensional response surface graphs were described. Optimum experimental conditions were calculated by Design-Expert 8.06. Results indicated that the optimum preparation conditions were as follows: 1.39 g of egg lecithin, 0.21 g of poloxamer 188, and 10.57% soybean oil for injection. Preparation of imperatorin lipid microspheres according to the optimum experimental conditions resulted in an overall desirability of 0.7286, with the particle size of 168 ± 0.54 nm, polydispersity index (PDI) of 0.138 ± 0.02, zeta potentials of −43.5 ± 0.5 mV, drug loading of 0.833 ± 0.27 mg·mL−1, and encapsulation efficiency of 90 ± 1.27%. The difference between the observed and predicted values of the overall desirability of the optimum formulation was in the range from 2.4% to 4.3%. Subsequently, scanning electron microscopy was used to observe the micromorphology of the imperatorin lipid microspheres, showing round globules of relatively uniform shape and sizes within 200 nm. The effect of imperatorin lipid microspheres on MDA-MB-231 proliferation was investigated by the MTT method. Furthermore, pharmacokinetics in Sprague-Dawley rats was evaluated using orbital bleeding. A sensitive and reliable liquid chromatography with the high-performance liquid chromatography (HPLC) method was established and validated for the quantification of imperatorin in rat plasma samples. The data were calculated by DAS (drug and statistics) Pharmacokinetic Software version 3.3.0 (Version 3.3.0, Shanghai, China). Results demonstrated that imperatorin lipid microspheres can significantly enhance the bioavailability of imperatorin and can significantly inhibit MDA-MB-231 cell proliferation. In conclusion, our results suggested that the response surface–central composite design is suitable for achieving an optimized lipid microsphere formulation. Imperatorin lipid microspheres can improve the bioavailability of imperatorin and better inhibit the proliferation of MDA-MB-231 cells as compared to imperatorin alone.
机译:Imperatorin是属于线性呋喃香豆素的化合物。 Imperatorin的抗肿瘤,抗菌,消炎和抗凝活性,抑制心肌肥大和其他药理作用引起了广泛的关注。然而,欧前胡素的水溶性有限,脂质溶解性更好。因此,我们决定设计和合成欧前胡素脂质微球,以优化制备条件。目的是通过纳米乳液技术开发和配制欧前胡素脂质微球,并应用响应表面-中心复合设计来优化欧前胡素脂质微球的配方。研究了卵磷脂,泊洛沙姆188和注射用大豆油的量对油相总百分比的影响。研究了因变量的综合效应,包括粒径,多分散指数,ζ电势,载药量和包封效率。将总期望数据拟合到二阶多项式方程,通过该方程描述了三维响应表面图。最佳实验条件由Design-Expert 8.06计算。结果表明,最佳制备条件为:鸡蛋卵磷脂1.39g,泊洛沙姆188 0.21g,注射用大豆油10.57%。根据最佳实验条件制备欧前胡素脂质微球的总体期望值为0.7286,粒径为168±0.54 nm,多分散指数(PDI)为0.138±0.02,ζ电位为-43.5±0.5 mV,载药量0.833±0.27 mg·mL -1 ,包封效率为90±1.27%。最佳配方的总体期望度的观察值与预测值之间的差异在2.4%至4.3%的范围内。随后,使用扫描电子显微镜观察了欧前胡素脂质微球的微观形态,显示出形状和大小相对均匀的圆形小球,直径在200 nm以内。 MTT法研究了欧前胡素脂质微球对MDA-MB-231增殖的影响。此外,使用眼眶出血评估了Sprague-Dawley大鼠的药代动力学。建立了高效液相色谱法(HPLC)灵敏可靠的液相色谱法,并验证了大鼠血浆样品中欧前胡素的定量方法。数据通过DAS(药物和统计学)Pharmacokinetic Software版本3.3.0(版本3.3.0,中国上海)计算。结果表明,欧前胡素脂质微球可以显着提高欧前胡素的生物利用度,并且可以显着抑制MDA-MB-231细胞的增殖。总之,我们的结果表明,响应表面-中心复合材料设计适合实现优化的脂质微球配方。与单独的欧前胡素相比,欧前胡素脂质微球可以提高欧前胡素的生物利用度并更好地抑制MDA-MB-231细胞的增殖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号